ALPG (WO 2022197890A1 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent WO2022197890A1, targeting ALPG (alkaline phosphatase, germ cell), also known as ALPPL2 or GCAP. ALPG is a GPI-anchored membrane enzyme belonging to the alkaline phosphatase family, sharing 90-98% genetic homology with placental and intestinal alkaline phosphatase isoforms. ALPG is primarily expressed at low levels in embryonic germ cells, testis, and thymus, but becomes aberrantly activated in multiple solid tumors including seminoma, ovarian, pancreatic, gastric, breast, and lung cancers. Unlike broadly expressed tissue-nonspecific alkaline phosphatase, ALPG exhibits highly restricted expression in normal adult tissues, making it a tumor-specific antigen with minimal off-target expression. The reference antibody is designed to selectively target ALPG-expressing cancer cells, leveraging this protein's unique tumor-associated expression pattern for therapeutic applications. This biosimilar provides researchers with a valuable tool for investigating ALPG biology in oncogenesis, studying alkaline phosphatase-mediated tumor progression, and exploring targeted immunotherapy strategies including CAR-T cell development. It supports research into germ cell tumors, solid tumor biology, and the development of novel cancer diagnostics and therapeutics targeting tumor-specific surface antigens.